Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population FDA advisors unanimously voted against expanding Pfizer’s Talzenna to a broader prostate cancer population without ...

Pfizer Inc. failed to convince advisers to the US Food and Drug Administration to support a dramatic expansion in the use of its prostate cancer drug, a setback that could scuttle the company’s ...

Pfizer exits Sanford, North Carolina jobs deal after Abzena acquisition. Drugmaker cites economic climate for not meeting Lee County hiring and investment goals.

However, Pfizer should be able to finance a buyout of Viking with its cash stockpile without breaking a sweat if it wanted to make a deal. Will Pfizer acquire one of these smaller drugmakers?

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient in a trial suffered a liver injury potentially caused by the drug.&nbsp… ...

The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at rival Pfizer, had told his GSK colleagues about the delay.